ClinicalTrials.gg
Sign In
Biological

Rituximab and Hyaluronidase Human clinical trials

A product of Rituximab; its studies count on that page too.

studies test it
7
open now
1
in phase 3
2
first study started
2017

How each study uses Rituximab and Hyaluronidase Human is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Rituximab and Hyaluronidase Human studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
22 Jun 2017 · RITUXAN HYCELA · BLA 761064 (FDA, Drugs@FDA)
European Union
2 Jun 1998 · MabThera · EMEA/H/C/000165 (EMA; as Rituximab)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Rituximab and Hyaluronidase Human
6
Rituximab/Hyaluronidase Human
6
Rituxan Hycela
6
Rituximab Plus Hyaluronidase
4
Rituximab/Hyaluronidase
4

Studies by the year they started

7 studies that test it; most in 2019 (2)

Studies that test Rituximab and Hyaluronidase Human, by start year
YearStudies
20171
20181
20192
20201
20211
20241

By phase

A phase 1/2 study counts in both.

Phase 1
2
Phase 2
3
Phase 3
2

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Lymphoma, Mantle-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Melanoma
1
Burkitt Lymphoma
1

Who runs them

Industry 0 · Other 7

Thomas Jefferson University (1) · ECOG-ACRIN Cancer Research Group (1) · Georgetown University (1) · Emory University (1) · National Cancer Institute (NCI) (1) · Academic and Community Cancer Research United (1) · Fred Hutchinson Cancer Center (1)

Often tested with

Tested in the same studies.

Venetoclax (3) · Lenalidomide (1) · Mosunetuzumab (1) · Polatuzumab vedotin (1)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 2, 1 in phase 3

Studies that test Rituximab and Hyaluronidase Human, phase 3 first.

Studies

Open first, then newest update. How each study uses Rituximab and Hyaluronidase Human is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 7

Given beside what is tested · 6 — Rituximab and Hyaluronidase Human is usual care or a partner of the new treatment
As the comparator · 1 — what is tested is compared with Rituximab and Hyaluronidase Human